BACKGROUND
ANCA-associated vasculitis (AAV) [1] , which includes Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), are rare potentially life-threatening multisystem autoimmune diseases. They are frequently grouped together for the purpose of treatment trials given their similar initial responses to standard therapy [2, 3] . Treatment for ANCAassociated vasculitis comprises remission induction and maintenance regimens [2] . The European League Against Rheumatism (EULAR) guidelines for the treatment of AAV suggest the use of cyclophosphamide or rituximab for remission induction therapy in new-onset organ-threatening or life-threatening AAV in combination with glucocorticoids [4] .
Cyclophosphamide with high dose glucocorticoids has been standard remission induction therapy for severe ANCA-associated vasculitis for over 30 years with remission rates of 80-90% [5, 6] and a current one year mortality of 10-25% [7] . However; cyclophosphamide is toxic causing infertility and malignancy. Rituximab is associated with similar remission induction rates to those achieved with cyclophosphamide and similar relapse rates over 18-24 months follow-up [8] [9] [10] [11] . However, the biological effect of rituximab is long and variable, and rituximab has been associated with hypogammaglobulinaemia in ANCA-associated vasculitis [12] . Due to its high cost the use of rituximab is restricted in some countries [13, 14] . For non-organ threatening AAV EULAR recommends methotrexate or Mycophenolate mofetil (MMF) in combination with glucocorticoids, although the level of evidence is rated as 1B, requiring further studies [4] . Methotrexate has similar efficacy to cyclophosphamide for remission induction in non-severe ANCA-associated vasculitis, but its toxicity precludes use in renal impairment [15, 16] . Mycophenolate mofetil is an alternative oral immunosuppressant with lymphocyte selective suppressive effects with a short duration of action, can be used in renal disease and unlike cyclophosphamide is not associated with urothelial malignancy or infertility. Small studies have suggested that MMF has efficacy for remission induction in ANCA-associated vasculitis, particularly in MPO-ANCA disease [17, 18] . Understanding the role of MMF as a remission induction agent in ANCA-associated vasculitis remains important. We conducted a randomised trial of adult and paediatric patients to investigate whether MMF was non-inferior to cyclophosphamide for remission induction in new patients with ANCA-associated vasculitis.
METHODS

Study design and patients
This trial was an open-label, two group, parallel design, randomised, non-inferiority trial involving 132 adult patients from 21 sites in six countries in Europe, Australia and New Zealand, and eight paediatric patients from four sites in the UK. All patients/parents provided written informed consent; and written assent where appropriate. Inclusion in this study required a new diagnosis of active ANCA-associated vasculitis (GPA or MPA) [1] with either a positive ANCA or histologically proven disease (see protocol for full inclusion details). Patients were excluded if they were aged < 6 years, had imminently life threatening vasculitis, rapidly declining renal function or an eGFR less than 15mls/min/m 2 or had received >2 weeks of oral cyclophosphamide or MMF or more than 1 pulse of IV CYC (15mg/kg). The trial protocol is available at http://vasculitis.org/images/documents/mycyc.pdf.
Patients were allocated in a 1:1 ratio to MMF or cyclophosphamide using a concealed system of minimization by: age greater than 60 years, the planned use of additional therapy with plasma exchange or solumedrol>0.5g at randomisation, estimated glomerular filtration rate (eGFR) less than 30mls/min/m 2 or greater than or equal to 30ml/min/m 2 with an allocation probability of 0.8. Although the minimization procedure did not include site as a stratification factor, the degree of balance of treatments within the sites was reasonable ( Supplementary table 1 [6, 9] . All patients were switched from their assigned study treatment to oral azathioprine 2mg/kg/day after remission had been achieved, between 3-6 months. Azathioprine with prednisolone 5mg/day was continued until study end at 18 months.
Outcomes
The primary outcome was remission by six months. [20] or Haycock-Schwartz formula in patients aged less than 16 years [21] . End Stage Renal Disease (ESRD) was defined as dialysis dependence for six weeks or more without subsequent recovery of renal function. Progressive disease was defined as on-going disease activity of sufficient severity to necessitate therapy escalation with a change in immunosuppression or intravenous methylprednisolone before remission.
Serious adverse events were collected as defined by the European Medicines Agency and Food and Drug Administration. ANCA negativity was determined by the reference range of the local laboratory for both indirect immunofluorescence and enzyme linked immunosorbant assays.
Statistical Analysis
The sample size estimate was based on a non-inferiority design. We assumed a remission rate of 85% with cyclophosphamide and specified a 12% absolute risk difference as the noninferiority margin (i.e. remission rate <73%) for MMF. Using these assumptions, we calculated that 124 patients were required to meet non-inferiority for the primary remission endpoint with a power of 80%, and a significance level of 5% in a non-inferiority test [22] .
Allowing for a 10% drop out rate we recruited 140 patients.
All endpoint analyses were by intention to treat with an additional pre-specified per protocol analysis of the primary endpoint. The primary and secondary remission endpoints (noninferiority) were assessed by calculating the risk difference (RD) of remission with corresponding two-sided 90% confidence intervals, consistent with the CONSORT extension for reporting of non-inferiority trials [23] . For the primary analyses, no attempts were made to impute missing data. Data were censored at withdrawal, loss to follow-up or death. Time to event analyses of remission (non-inferiority) were performed using a Cox proportional hazards model with a hazard ratio (HR) of 0.85 as the non-inferiority margin. Relapse rates (superiority) were compared by calculating the incidence rate ratio (relapses per patient per year) and corresponding 95% confidence interval with significance estimates derived from the binomial distribution test. For safety and other efficacy endpoints comparison of proportions was performed using the Fisher mid-p test, as recommended [24] . All continuous variables are presented as mean ± SD or median (IQR) as appropriate to their distribution, and categorical variables are presented as count (%). All analyses were conducted using Stata SE version 15 (College Station TX).
RESULTS
Patients
Between * Renal involvement is defined as one or more renal BVAS items present at entry excluding hypertension alone. Lung and ENT require one or more lung or ENT BVAS items present at entry respectively. # Baseline BVAS data was missing in 1 subject in the MMF group.
Primary outcome
The primary endpoint of remission with glucocorticoid compliance within 6 months occurred in 47 patients, including 1 child, (67%) in the MMF and 43 (61%), including 1 child, in the cyclophosphamide groups (Risk Difference (RD) 5.7%, 90%CI -7.5% to19%). Given the specified non-inferiority margin of -12%, the lower bound of the 90% CI of -7.5% established non-inferiority ( Figure 2 ).
In a pre-specified analysis restricted to per-protocol treated patients, 43 remissions (74%) occurred in 58 mycophenolate patients, compared to 33 remissions (62%) in 53 cyclophosphamide patients (RD 11.9%, 90% CI -2.6% to 26.3%, non inferior) ( Figure 2 ). There was no evidence of interaction by PR3 ANCA positivity, age, renal function and the use of additional induction therapies with the primary endpoint ( Figure 2 ).
Secondary efficacy outcomes
Secondary efficacy outcomes are summarised in Figure 3 , supplementary in the MMF and 55 (79%) in the cyclophosphamide groups (RD 8.6%, 90%CI -1.8% to 19%).
Remission at any time during trial follow up irrespective of steroid compliance occurred in 63 patients (90%), including 2 children, in the MMF and 64 (92%), including 2 children, of the cyclophosphamide groups (RD -1.4%, 90%CI -9.5% to 6.6%). There was no statistically significant difference in cumulative glucocorticoid exposure during the trial (MMF 6194 ± 317 mg, CYC 5800 ± 234 mg, p=0.32) ( Supplementary Figure 1a) . Two patients in both groups progressed to ESRD and eGFR at 18 months did not differ between groups (MMF group 68±4 ml/min, cyclophosphamide group 64±4 ml/min, p=0.46) ( Supplementary Figure 1b) . There was no difference in disease and treatment related damage assessed by the vasculitis damage index at study end between the two groups (MMF=1, IQR 1 to 3; CYC=2, IQR 1 to 3; p=0.80).
Safety outcomes
Serious adverse events occurred in 35 in the MMF (50% patients, 73 events) and 28 in the cyclophosphamide groups (40% patients, 64 events) and are summarised in Table 2 . There were no significant differences in serious infections, death, thromboembolism, malignancy or serious disease related events between the two groups. 
Discussion
In this randomised trial of remission induction in ANCA-associated vasculitis, excluding patients on dialysis or with life-threatening disease, MMF was non-inferior to pulsed cyclophosphamide. The relatively low remission rate for the primary outcome can be attributed to the stringent requirement for adherence to glucocorticoid taper as shown by others, [8] and the higher rate of the secondary endpoint of remission irrespective of glucocorticoid adherence is consistent with previous reports where the glucocorticoid taper was not a component of the remission definition. [6, 25] Our results demonstrate that MMF represents an alternative to cyclophosphamide for remission induction in AAV. This study provides further evidence to support the EULAR guidelines on management of AAV.
Our findings of the efficacy of MMF for remission induction are consistent with previous MMF induction studies in AAV [18, 26, 27] . After remission, relapses occurred earlier and more frequently in the MMF group (33%) compared to the cyclophosphamide group (19%).
Although this was a secondary outcome and the trial was not designed or powered to detect differences in relapse rate, this observation is consistent with the increase in early relapses observed with methotrexate compared to cyclophosphamide [15] , higher relapse risk with lower cumulative cyclophosphamide exposure [28] , and the higher rate of relapse with MMF compared to AZA when used for maintenance therapy [29] . While treatment with MMF may be associated with a higher risk of relapse compared to pulsed cyclophosphamide, this increased risk may be acceptable to avoid the potential adverse effects of cyclophosphamide particularly when the baseline risk of relapse is low (e.g. in patients that are MPO-ANCA positive) or if rituximab is unavailable.
The use of MMF alongside standard dose glucocorticoids offers advantages over cyclophosphamide in terms of fertility preservation for younger patients and potentially lower malignancy rates in elderly populations at greatest risk [30] . Unlike rituximab (an approved alternative to cyclophosphamide for severe ANCA-associated vasculitis), MMF is an oral drug, has a short duration of action, and unlike methotrexate, can be used in moderate or severe renal disease and was not associated with slower time to remission compared to cyclophosphamide [15] . However, there were no differences in this study in the number of adverse events between the two groups.
Our trial has several notable strengths. It is the largest randomised trial in AAV to assess the use of MMF for remission induction. Patients were recruited from 21 countries, and the trial cohort was representative of other trial populations in AAV. This is the first randomised trial in AAV to include children, although the small number of paediatric participants (n=8) limits the inferences we might draw concerning relative efficacy of MMF in this population. The primary endpoint was achieved in 1 of 4 paediatric patients in both CYC and MMF groups and response rates were similar in the MMF and CYC groups in children. Compliance was a contributory factor to the lower remission rate in children, and because of the small sample size we have not drawn conclusions of efficacy in this subpopulation.
The strengths of our trial should be viewed against its limitations. The trial was not blinded, although the similar rates of glucocorticoid adherence and exposure, progressive disease, rescue therapy requirement, ANCA negativity and the rates of ESRD is reassuring. Treating clinicians were allowed to include plasma exchange or additional solumedrol at entry; however there were no differences in additional treatments used between the two groups.
The short follow up of 18 months in this study may have reduced the ability to detect the true effect on relapse and malignancy rates in the longer term. It should be noted in another study MMF was inferior to azathioprine for remission maintenance after cyclophosphamide induction, with more relapses in the MMF group, [29] . Following remission induction all patients in our trial received azathioprine and glucocorticoid maintenance therapy. There is limited evidence for using azathioprine as induction therapy in AAV. It has been used in addition to corticosteroids for newly diagnosed non-severe eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis , or polyarteritis nodosa, however the addition of azathioprine in these patients did not improve remission rates or reduce relapse [31] .
Since initiation of the trial, it has become common to use rituximab as an alternative to cyclophosphamide induction therapy, which may question the use of MMF as an alternative induction therapy. However, rituximab is expensive and its use is restricted in many The lower bound 90% CI did not cross the non-inferiority margin of 12% for the primary endpoint and per protocol analyses demonstrating non-inferiority. The lower bound 90% CI only crossed the non-inferiority margin for patients with GFR<30ml/min but the upper-bound 90%CI exceeded 0. This would be described as 'inconclusive' and given this is a secondary analysis of a sub-group we are unable to draw any inference from this other than the p value for interaction being non-significant. The diamonds represent the absolute risk ratio, horizontal black lines represent 90% confidence intervals. The left side of blue shaded area represents the lower limit of non-inferiority margin (-12%). 
D. Steroid Taper
The figure shows the protocolised and actual steroid tapers within each study group. The black line represents the protocolised dose by weight (calculated as mean weight of the entire trial population x 1 mg/kg) and the stratified lines represent per treatment group equivalents (mean doses). This has been restricted to the first 6 months consistent with the primary outcome.
Figure S2
c. Time to relapse stratified by ANCA-PR3 and ANCA-MPO subtypes
More relapses occurred in the MMF group than the cyclophosphamide group. A post-hoc subgroup analysis found the higher relapse rate in MMF patients was accounted for by more relapses in PR3 ANCA patients, but not MPO ANCA patients. However, the study was not designed or powered to detect differences in relapses rates. There was no evidence that the effect of MMF on relapse differed by ANCA subtype (p=0.52 for interaction)
